The present invention provides 4-(( R ) -2-{[6-(( S ) -3-methoxy-pyrrolidin-1-yl) -2-phenyl for use as a medicament by subcutaneous or intradermal administration. -Pyrimidine-4-carbonyl] -amino} -3-phosphono-propionyl) -piperazine-1-carboxylic acid butyl ester, (1 S , 2 S , 3 R , 5 S ) -3- [ 7 - [(1 R, 2 S) -2- (3,4- difluorophenyl) cyclopropyl] -5- (propyl thio) -3 H - [1,2,3] triazolo [4, 5- d ] pyrimidin-3-yl] -5- (2-hydroxyethoxy) cyclopentane-1,2-diol, and (1 S , 2 R , 3 S , 4 R ) -4- [7 - [(1 R, 2 S ) -2- (3,4- difluorophenyl) cyclopropyl] -5- (propyl thio) -3 H - [1,2,3] triazolo [4,5- - d] pyrimidin-3-yl] cyclopentane-1,2,3-triol, or P2Y 12 receptor antagonist is selected from the group consisting of a pharmaceutically acceptable salt thereof.본 발명은 피하 또는 피내 투여에 의해 약제로서 사용하기 위한, 4-((R)-2-{[6-((S)-3-메톡시-피롤리딘-1-일)-2-페닐-피리미딘-4-카르보닐]-아미노}-3-포스포노-프로피오닐)-피페라진-1-카르복실산 부틸 에스테르, (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-디플루오로페닐)시클로프로필아미노]-5-(프로필티오)-3H-[1,2,3]트리아졸로[4,5-d]피리미딘-3-일]-5-(2-히드록시에톡시)시클로펜탄-1,2-디올, 및 (1S,2R,3S,4R)-4-[7-[(1R,2S)-2-(3,4-디플루오로페닐)시클로프로필아미노]-5-(프로필티오)-3H-[1,2,3]트리아졸로[4,5-d]피리미딘-3-일]시클로펜탄-1,2,3-트리올, 또는 이의 약학적으로 허용가능한 염으로 이루어지는 군에서 선택되는 P2Y12 수용체 안타고니스트에 관한 것이다.
